Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart danger lurks in newer cancer pills?

NCT ID NCT07174141

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times

Summary

This study tracks 100 patients taking newer BTK inhibitor drugs (acalabrutinib or zanubrutinib) for blood cancers like leukemia or lymphoma. Researchers want to find out how often these drugs cause heart rhythm problems or high blood pressure, and who is most at risk. Participants will have eye exams and blood tests over one year to look for early warning signs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Dijon Bourgogne

    RECRUITING

    Dijon, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Second-generation Bruton's tyrosine kinase inhibitors (acalabrutinib, zanubrutinib)

What this could lead to

If successful, this could help doctors identify which patients are at highest risk for heart problems from these drugs, leading to better monitoring and care.

What could go wrong

This is a small, single-center observational study, not a treatment trial. It aims to gather information, not test a new therapy, so it won't directly change treatment.

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia mantle cell lymphoma non-Hodgkin lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT WITH SECOND-GENERATION BRUTON'S TYROSINE KINASE INHIBITORS (ACALABRUTINIB, ZANUBRUTINIB)